Centre for Addiction and Mental Health, Toronto.
Am J Psychiatry. 2013 May;170(5):471-5. doi: 10.1176/appi.ajp.2012.12111475.
Sexual dysfunction is common among women with schizophrenia treated with antipsychotic medication. Multiple factors influence sexual function and reproductive health in this patient population, including the effects of medications on prolactin secretion and the complexities of making contraceptive decisions in the context of a serious mental illness. The author explores the causes and management of loss of libido as illustrated by a case vignette and describes the course and outcome of a clinical intervention that was implemented to alleviate the sexual dysfunction. Possible approaches and potential pitfalls of the intervention are described. Clinicians must be open to discussions regarding sexual concerns, relationships with sexual partners, and reproductive issues with women suffering from schizophrenia. Both patients and clinicians need to be aware of unintended effects of intervention. Opportunities exist for improved education among clinicians to achieve a more proactive approach to sexual health in women receiving antipsychotic medication.
性障碍在接受抗精神病药物治疗的精神分裂症女性中很常见。多种因素会影响该患者群体的性功能和生殖健康,包括药物对催乳素分泌的影响,以及在严重精神疾病背景下做出避孕决策的复杂性。作者通过案例简述探讨了性欲丧失的原因和管理,并描述了为缓解性功能障碍而实施的临床干预的过程和结果。描述了干预措施的可能方法和潜在陷阱。临床医生必须愿意讨论与性问题、与性伴侣的关系以及患有精神分裂症的女性的生殖问题。患者和临床医生都需要意识到干预的意外影响。为改善接受抗精神病药物治疗的女性的性健康,为临床医生提供了更多的教育机会,以采取更积极主动的方法。